Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 10,681,565	$ 8,822,226
General and administrative	8,012,085	3,165,331
Total operating expenses	18,693,650	11,987,557
Loss from operations	(18,693,650)	(11,987,557)
Other income:
Interest income	126,416	117,329
Total other income	126,416	117,329
Net loss	(18,567,234)	(11,870,228)
Preferred stock dividend		(875,359)
Deemed dividend for beneficial conversion feature of Series A Preferred Stock		(23,929,751)
Net loss applicable to common stock	$ (18,567,234)	$ (36,675,338)
Net loss applicable to common stock per share, basic and diluted (in Dollars per share)	$ (0.91)	$ (5.31)
Weighted average common shares outstanding, basic and diluted (in Shares)	20,425,162	6,904,983
Net loss	$ (18,567,234)	$ (11,870,228)
Foreign currency translation adjustments	(51,538)
Comprehensive loss	$ (18,618,772)	$ (11,870,228)